Literature DB >> 26772211

Crystal Formation in Inflammation.

Bernardo S Franklin1, Matthew S Mangan1,2, Eicke Latz1,2,3,4.   

Abstract

The formation and accumulation of crystalline material in tissues is a hallmark of many metabolic and inflammatory conditions. The discovery that the phase transition of physiologically soluble substances to their crystalline forms can be detected by the immune system and activate innate immune pathways has revolutionized our understanding of how crystals cause inflammation. It is now appreciated that crystals are part of the pathogenesis of numerous diseases, including gout, silicosis, asbestosis, and atherosclerosis. In this review we discuss current knowledge of the complex mechanisms of crystal formation in diseased tissues and their interplay with the nutrients, metabolites, and immune cells that account for crystal-induced inflammation.

Entities:  

Keywords:  air pollution; cardiovascular diseases; gout; interleukin-1; malaria; nanotechnology

Mesh:

Substances:

Year:  2016        PMID: 26772211     DOI: 10.1146/annurev-immunol-041015-055539

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  40 in total

1.  Genetic mitochondrial glycine amidinotransferase protein aggregate formation triggers microparticle sensing and kidney failure.

Authors:  Shrikant R Mulay; Hans-Joachim Anders
Journal:  Ann Transl Med       Date:  2018-08

2.  Mitochondria Permeability Transition versus Necroptosis in Oxalate-Induced AKI.

Authors:  Shrikant Ramesh Mulay; Mohsen M Honarpisheh; Orestes Foresto-Neto; Chongxu Shi; Jyaysi Desai; Zhi Bo Zhao; Julian A Marschner; Bastian Popper; Ewa Miriam Buhl; Peter Boor; Andreas Linkermann; Helen Liapis; Rostyslav Bilyy; Martin Herrmann; Paola Romagnani; Ilya Belevich; Eija Jokitalo; Jan U Becker; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2019-07-11       Impact factor: 10.121

3.  The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.

Authors:  Maryam Rashidi; Daniel S Simpson; Anne Hempel; Daniel Frank; Emma Petrie; Angelina Vince; Rebecca Feltham; Jane Murphy; Simon M Chatfield; Guy S Salvesen; James M Murphy; Ian P Wicks; James E Vince
Journal:  J Immunol       Date:  2019-06-17       Impact factor: 5.422

4.  Suppression of Syk activation by resveratrol inhibits MSU crystal-induced inflammation in human monocytes.

Authors:  Yeon-Ho Chung; Hee Young Kim; Bo Ruem Yoon; Yeon Jun Kang; Won-Woo Lee
Journal:  J Mol Med (Berl)       Date:  2019-01-12       Impact factor: 4.599

Review 5.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

6.  Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation.

Authors:  Eric V Dang; Jeffrey G McDonald; David W Russell; Jason G Cyster
Journal:  Cell       Date:  2017-10-12       Impact factor: 41.582

Review 7.  Multiple Pathways for Pathological Calcification in the Human Body.

Authors:  Netta Vidavsky; Jennie A M R Kunitake; Lara A Estroff
Journal:  Adv Healthc Mater       Date:  2020-12-04       Impact factor: 9.933

Review 8.  Novel Insights into Crystal-Induced Kidney Injury.

Authors:  Shrikant R Mulay; Chongxu Shi; Xiaoyuan Ma; Hans Joachim Anders
Journal:  Kidney Dis (Basel)       Date:  2018-04-03

9.  Mechanisms of Environment-Induced Autoimmunity.

Authors:  K Michael Pollard; David M Cauvi; Jessica M Mayeux; Christopher B Toomey; Amy K Peiss; Per Hultman; Dwight H Kono
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-28       Impact factor: 13.820

Review 10.  The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage.

Authors:  Ewa Kwiatkowska; Leszek Domański; Violetta Dziedziejko; Anna Kajdy; Katarzyna Stefańska; Sebastian Kwiatkowski
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.